Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

Keita Kawakado; Tomoki Tamura; Masamoto Nakanishi; Go Makimoto; Shoichi Kuyama

doi:10.2169/internalmedicine.7425-21

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

Keita Kawakado, Tomoki Tamura, Masamoto Nakanishi, Go Makimoto, Shoichi Kuyama

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 63-year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.

Original language	English
Pages (from-to)	3941-3945
Number of pages	5
Journal	Internal Medicine
Volume	60
Issue number	24
DOIs	https://doi.org/10.2169/internalmedicine.7425-21
Publication status	Published - 2021
Externally published	Yes

Keywords

Non-small-cell lung cancer
Pembrolizumab
Retrobulbar optic neuritis

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.7425-21

Cite this

@article{4194006c834348bc8259a4cb3ecd6c9d,

title = "Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma",

abstract = "Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 63-year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.",

keywords = "Non-small-cell lung cancer, Pembrolizumab, Retrobulbar optic neuritis",

author = "Keita Kawakado and Tomoki Tamura and Masamoto Nakanishi and Go Makimoto and Shoichi Kuyama",

note = "Funding Information: We thank the patient and Dr. K. Shibata for the ophthalmic diagnosis. Publisher Copyright: {\textcopyright} 2021 The Japanese Society of Internal Medicine Intern Med 60: 3941-3945, 2021",

year = "2021",

doi = "10.2169/internalmedicine.7425-21",

language = "English",

volume = "60",

pages = "3941--3945",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "24",

}

TY - JOUR

T1 - Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

AU - Kawakado, Keita

AU - Tamura, Tomoki

AU - Nakanishi, Masamoto

AU - Makimoto, Go

AU - Kuyama, Shoichi

PY - 2021

Y1 - 2021

N2 - Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 63-year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.

AB - Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 63-year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.

KW - Non-small-cell lung cancer

KW - Pembrolizumab

KW - Retrobulbar optic neuritis

UR - http://www.scopus.com/inward/record.url?scp=85121898083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121898083&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.7425-21

DO - 10.2169/internalmedicine.7425-21

M3 - Article

C2 - 34148963

AN - SCOPUS:85121898083

SN - 0918-2918

VL - 60

SP - 3941

EP - 3945

JO - Internal Medicine

JF - Internal Medicine

IS - 24

ER -

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this